KEI Comments on NIH Proposal to Require License Holders to Provide Access Plans
NIH
KEI Submissions to the NIH on the Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning
The National Institutes of Health (NIH) Office of Science Policy (OSP) posted a Request for Information (RFI) on the Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning. The draft policy seeks, “to promote access to products stemming… Continue Reading
KEI Comments on NIH Exclusive License to INTcRON
On Tuesday June 4, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding “Prospective Grant of an Exclusive Patent License: T Cell Receptor Fusion Proteins for the Treatment of Cancer” (89 FR 43859) to… Continue Reading
NIH announces new policy to deal with access to NIH licensed inventions
In a notice to the federal register, the NIH is announcing a new policy to address issues of access and equity in the licensing of NIH patented inventions. (The Federal Register notice is here. Secretary Becerra announcement is here). The… Continue Reading
Sanctions for Non Disclosure, as Set Out in Article 6 of the WIPO Basic Proposal on Intellectual Property, Genetic Resources and Traditional Knowledge, Should Include Possible Revocation of a Patent
On May 15, 2024, Knowledge Ecology International published an article on “Sanctions for Non Disclosure, as Set Out in Article 6 of the WIPO Basic Proposal on Intellectual Property, Genetic Resources and Traditional Knowledge, Should Include Possible Revocation of a… Continue Reading
KEI Comments to the NIH on Exclusive License to UK Firm Poolbeg Pharma
On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a UK-based company. The license concerns, “Adoptive T Cell Therapy Products… Continue Reading
KEI Comments to the NIH License on Gene Therapy to Marble Therapeutics
Today Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Adoptive Cell Therapy for the Treatment of Cancer” (89 FR 8438). The wordwide, exclusive license… Continue Reading
Scarlet TCR: Comments on a NIH prospective exclusive patent license for treatment of HPV cancers
Updates: Senator Sanders Sends Letter to HHS Inspector General Urging Investigation of Exclusive Patent License for NIH-funded Cancer Therapy, Press Release. October 23, 2023. David Dayen, “Sanders Seeks Investigation of NIH Licensing Practices: The senator wants the inspector general to… Continue Reading
KEI Comments to CMS Regarding Imbruvica (INN:Ibrutinib) R&D (regarding Medicare pricing negotiations)
On October 2, 2023, Knowledge Ecology International submitted written comments to the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Medicare Price Negotiation public consultation process. CMS is hosting a series of patient-focused listening sessions this fall,… Continue Reading
KEI August 18, 2023 Comments to the NIH licensing practices highlight failure to enforce Section 209 restrictions on exclusivity, transparency concerns, and KEI’s past engagement
As a part of the workshop hosted by the National Institutes of Health (NIH) on July 31, 2023 on the topic of, “Transforming Discoveries Into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer,” the NIH solicited public comments. In addition… Continue Reading